Skip to main content

Table 3 Univariate analysis of 3-year survival

From: GP96 is over-expressed in oral cavity cancer and is a poor prognostic indicator for patients receiving radiotherapy

   LRC (%) p DMFS (%) p DFS (%) p DSS (%) p OS (%) p
Stage I-II
III-IV
81.8
66.4
0.245 84.6
77.5
0.548 69.2
55.1
0.282 76.9
60.4
0.208 76.9
54.2
0.033
T stage T1-2
T3-4
77.5
61.6
0.145 81.9
75.6
0.458 66.3
49.6
0.139 71.3
55.9
0.144 66.7
50.4
0.021
N stage N0-1
N2-3
74.1
62.2
0.196 87.5
66.8
0.023 66.7
45.8
0.024 75.8
46.6
0.007 72.3
40.0
0.002
Depth (millimeters) ≤10
> 10
61.2
74.8
0.367 90.0
71.7
0.118 55.1
58.8
0.938 67.9
60.3
0.694 62.4
55.1
0.417
Differentiation Well
Moderate
Poor
72.0
67.1
75.0
0.818 86.6
82.5
37.5
0.003 66.0
56.6
37.5
0.264 70.2
64.1
37.5
0.203 66.7
56.8
37.5
0.580
Nodal ECS No
Yes
78.1
53.8
0.049 87.9
63.7
0.019 70.7
38.3
0.005 79.5
39.4
0.001 75.6
34.3
0.001
Skin invasion No
Yes
71.6
41.7
0.153 81.3
51.4
0.076 60.5
28.6
0.071 67.0
28.6
0.033 60.8
28.6
0.204
Bone invasion No
Yes
71.6
62.7
0.407 74.5
90.7
0.226 57.7
56.9
0.871 64.2
60.2
0.940 58.9
54.8
0.251
Perineural invasion No
Yes
68.1
71.9
0.717 81.3
69.2
0.295 58.6
51.9
0.349 67.8
50.0
0.170 62.0
45.8
0.318
Blood vessel invasion No
Yes
67.5
80.0
0.729 78.0
75.0
0.999 56.0
60.0
0.891 62.4
60.0
0.909 56.6
60.0
0.741
Lymphatic vessel invasion No
Yes
67.6
75.8
0.845 81.9
55.6
0.014 58.1
46.3
0.218 65.1
45.8
0.106 59.6
41.7
0.117
Margin status (millimeters) ≥ 5
< 5
67.1
80.8
0.406 77.3
84.6
0.737 55.4
68.4
0.517 59.2
83.3
0.152 54.1
65.9
0.157
Concurrent chemotherapy No
Yes
70.8
67.8
0.613 89.3
66.0
0.014 65.2
48.9
0.071 72.6
52.4
0.506 70.6
44.3
0.022
GP96 overexpression No
Yes
90.2
58.7
0.008 95.8
69.5
0.018 86.5
44.7
0.001 95.7
49.0
0.001 87.5
44.9
0.003
  1. Abbreviation: LRC = locoregional control; DMFS = distant metastasis-free survival; DFS = disease-free survival; DSS = disease-specific survival; OS = overall-survival; ECS = extra-capsular spreading.